this post was submitted on 27 Feb 2024
427 points (98.2% liked)
Technology
59597 readers
3056 users here now
This is a most excellent place for technology news and articles.
Our Rules
- Follow the lemmy.world rules.
- Only tech related content.
- Be excellent to each another!
- Mod approved content bots can post up to 10 articles per day.
- Threads asking for personal tech support may be deleted.
- Politics threads may be removed.
- No memes allowed as posts, OK to post as comments.
- Only approved bots from the list below, to ask if your bot can be added please contact us.
- Check for duplicates before posting, duplicates may be removed
Approved Bots
founded 1 year ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
The FTC has at least been going after companies again, but their targeting priorities seem very strange. They seem to like picking impossible fights they can't win, rather than cases like these.
Regulatory theatre
Antitrust isn't about just a binary win or loss. A lot of the cases, the FTC/DOJ has been losing because of concessions made by the merging parties. By showing a willingness to fight on mergers, the FTC is influencing the structure of mergers where merging companies are now willing to specifically identify business units to be spun off or sold.
Microsoft/Activision agreed to terms that would prevent their biggest titles from going Xbox exclusive. The Court that allowed the merger to go through specifically cited public statements and legally binding contracts as part of the reason why that deal could go through. The willingness to fight forced Microsoft to preserve some level of competition.
And a lot of the other deals haven't gone through. The FTC successfully blocked the merger between Penguin Random House and Simon & Schuster. The Nvidia/ARM deal was blocked. So was the Amazon/iRobot deal.
The smaller deals they've successfully blocked are also shifting the legal landscape on how courts view these deals. Nobody outside of biotech is familiar with names like Illumina/Grail, but that FTC win is a big deal for applying to a vertical merger between companies operating at different points of a supply chain, rather than a horizontal merger between direct competitors.
The heightened regulatory scrutiny is chilling mergers, even before they get to the point of FTC review, too. So there is some concrete effect here.